Skip to content

Clinical Study of SMILE 4.0-VISULYZE in Correcting Refractive Errors

Clinical Study of SMILE 4.0-VISULYZE in Correcting Refractive Errors

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06982807
Enrollment
600
Registered
2025-05-21
Start date
2024-11-01
Completion date
2026-12-31
Last updated
2025-05-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractive Surgery, Myopia; Refractive Error

Brief summary

The aim of this study is to further optimize the surgical input parameters for patients undergoing Small Incision Lenticule Extraction (SMILE) using the regression model established by the SMILE 4.0-VISULYZE system, thereby achieving satisfactory postoperative refractive outcomes. In this study, patients scheduled for SMILE surgery at the investigators' hospital will be divided into two groups: a conventional group, where the input parameters are adjusted based on historical experience according to the patient's refractive error, and a 4.0-VISULYZE group, where the input parameters are optimized using the SMILE 4.0-VISULYZE system. The investigators will compare the postoperative outcomes between the two groups, including uncorrected visual acuity (UCVA), best-corrected visual acuity (BCVA), spherical power, cylindrical power, spherical equivalent (SE), and the proportions of patients achieving postoperative visual acuity ≥0.8, ≥1.0, and ≥1.2 at 1 day, 10 days, 1 month, 3 months, 6 months, and 1 year post-surgery. Additionally, the investigators will evaluate the proportions of patients with postoperative SE within ±0.50D and ±1.0D, as well as postoperative cylindrical power within ±0.50D and ±1.0D, to assess the efficacy and safety of the SMILE 4.0-VISULYZE system in treating refractive errors.

Interventions

PROCEDUREGroup 4.0-VISULYZE

The 4.0-VISULYZE group had their infusion rates precisely calibrated using 4.0-VISULYZE

The traditional group had their infusion rates based on past experience.

Sponsors

Affiliated Hospital of Nantong University
Lead SponsorOTHER

Study design

Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

1. The diopter is relatively stable (the diopter increases within -0.50D per year for 2 consecutive years); 2. Age: 18 to 40 years old; 3. Optimal preoperative corrected visual acuity ≥4.8; 4. More than 2 weeks for soft contact lenses and more than 3 months for hard contact lenses before surgery 5. Patients who are willing to perform SMILE surgery

Exclusion criteria

1. Patients with history of eye surgery and trauma; 2. Patients with keratoconus tendency; 3. systemic connective tissue diseases and autoimmune diseases; 4. Patients with high blood pressure, diabetes and heart disease history; 5. Other eye disease history such as uveitis, scleritis and other eye inflammation patients; 6. Patients with scar constitution.

Design outcomes

Primary

MeasureTime frameDescription
spherical equivalentpreoperative, postoperative 10 days, 1, 3, 6, 12 monthsUse autorefractor-keratometer and phoroptor to measure degree of myopia and astigmatism,then derive the spherical equivalent.

Secondary

MeasureTime frameDescription
uncorrected distance visual acuitypreoperative, postoperative 10 days, 1, 3, 6, 12 monthsUse a standardized visual acuity chart (e.g., Snellen or LogMAR chart)
corrected distance visualacuitypreoperative, postoperative 10 days, 1, 3, 6, 12 monthsUse autorefractor-keratometer and phoroptor

Countries

China

Contacts

Primary ContactYing Yu, professor
yuying.2009@163.com86 15996621616

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026